CorMedix Stock Price, News & Analysis (NYSEAMERICAN:CRMD)

$0.32 +0.01 (+3.23 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$0.31
Today's Range$0.27 - $0.34
52-Week Range$0.27 - $2.30
Volume8.94 million shs
Average Volume1.29 million shs
Market Capitalization$25.91 million
P/E Ratio-0.51
Dividend YieldN/A
Beta0.18

About CorMedix (NYSEAMERICAN:CRMD)

CorMedix logoCorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:CRMD
CUSIPN/A
Phone+1-908-5179500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-0.508196721311475
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.61)
Net IncomeN/A
Net Margins-16,300.49%
Return on Equity-318.95%
Return on Assets-227.65%

Miscellaneous

EmployeesN/A
Outstanding Shares67,030,000

CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) announced its earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.08. The biotechnology company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.05 million. CorMedix had a negative return on equity of 318.95% and a negative net margin of 16,300.49%. View CorMedix's Earnings History.

When will CorMedix make its next earnings announcement?

CorMedix is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for CorMedix.

Where is CorMedix's stock going? Where will CorMedix's stock price be in 2018?

3 brokerages have issued twelve-month price targets for CorMedix's shares. Their forecasts range from $3.00 to $4.00. On average, they anticipate CorMedix's share price to reach $3.50 in the next year. View Analyst Ratings for CorMedix.

Are investors shorting CorMedix?

CorMedix saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 4,692,803 shares, an increase of 8.3% from the January 12th total of 4,332,544 shares. Based on an average daily trading volume, of 651,504 shares, the short-interest ratio is presently 7.2 days. Approximately 7.6% of the company's shares are sold short.

Who are some of CorMedix's key competitors?

Who are CorMedix's key executives?

CorMedix's management team includes the folowing people:

  • Myron M. Kaplan, Chairman of the Board (Age 70)
  • Randy Milby, Chief Executive Officer, Director (Age 61)
  • Robert W. Cook, Chief Financial Officer (Age 60)
  • Antony E. Pfaffle M.D., Chief Scientific Officer, Director (Age 51)
  • Khoso Baluch, Director
  • Gary A. Gelbfish M.D., Director (Age 54)
  • Mehmood Khan M.D., Director (Age 58)
  • Janet M. Dillione, Independent Director (Age 55)
  • Matthew P. Duffy, Independent Director (Age 52)

Who owns CorMedix stock?

CorMedix's stock is owned by a number of of institutional and retail investors. Top institutional investors include Spinnaker Capital LLC (0.60%) and Virtu Financial LLC (0.34%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Matthew Duffy, Mehmood Khan, Myron Kaplan, Robert W Cook, Steven W Lefkowitz and Taunia Markvicka. View Institutional Ownership Trends for CorMedix.

Who bought CorMedix stock? Who is buying CorMedix stock?

CorMedix's stock was bought by a variety of institutional investors in the last quarter, including Spinnaker Capital LLC and Virtu Financial LLC. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook, Steven W Lefkowitz and Taunia Markvicka. View Insider Buying and Selling for CorMedix.

How do I buy CorMedix stock?

Shares of CorMedix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CorMedix's stock price today?

One share of CorMedix stock can currently be purchased for approximately $0.32.

How big of a company is CorMedix?

CorMedix has a market capitalization of $25.91 million.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.


MarketBeat Community Rating for CorMedix (CRMD)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  134 (Vote Underperform)
Total Votes:  267
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CorMedix (NYSEAMERICAN:CRMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.50$3.67$3.67$3.33
Price Target Upside: 448.42% upside474.53% upside474.53% upside813.99% upside

CorMedix (NYSEAMERICAN:CRMD) Consensus Price Target History

Price Target History for CorMedix (NYSEAMERICAN:CRMD)

CorMedix (NYSEAMERICAN:CRMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/16/2017HC WainwrightSet Price TargetBuy$4.00View Rating Details
8/10/2017Rodman & RenshawLower Price TargetBuy -> Buy$5.00 -> $3.00View Rating Details
4/24/2017FBR & CoReiterated RatingBuyView Rating Details
(Data available from 2/23/2016 forward)

Earnings

CorMedix (NYSEAMERICAN:CRMD) Earnings History and Estimates Chart

Earnings by Quarter for CorMedix (NYSEAMERICAN:CRMD)

CorMedix (NYSEAMERICAN CRMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018($0.13)N/AView Earnings Details
8/9/2017Q2 2017($0.16)($0.14)$0.15 million$0.14 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.15)($0.19)$0.09 million$0.04 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.22)($0.16)$0.06 million$0.12 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.15)($0.23)$0.05 million$0.04 millionViewN/AView Earnings Details
8/5/2016Q216($0.11)($0.13)$119.97 million$16.51 millionViewN/AView Earnings Details
5/10/2016Q1($0.09)($0.12)$0.11 million$0.04 millionViewN/AView Earnings Details
3/16/2016Q4 2015($0.16)($0.11)$0.07 million$0.02 millionViewN/AView Earnings Details
11/12/2015Q3($0.13)($0.14)$0.12 million$0.04 millionViewListenView Earnings Details
8/6/2015Q2 2015($0.13)($0.13)$0.08 million$0.12 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.10)($0.23)$0.07 million$0.03 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.12)($0.09)$0.08 million$0.09 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.09)($0.09)$0.08 million$0.05 millionViewN/AView Earnings Details
8/14/2014Q2 2014($0.13)($0.26)$0.02 million$0.04 millionViewN/AView Earnings Details
5/15/2014Q1 2014($0.16)$0.01 millionViewN/AView Earnings Details
3/31/2014Q4 2013($0.22)ViewN/AView Earnings Details
11/19/2013Q3 2013($0.18)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.15)ViewN/AView Earnings Details
5/14/2013Q1 2013($0.10)ViewN/AView Earnings Details
3/27/2013Q4 2012($0.10)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.06)ViewN/AView Earnings Details
8/13/2012Q2 2012($0.05)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.08)ViewN/AView Earnings Details
3/19/2012Q4 2011$0.03ViewN/AView Earnings Details
11/10/2011Q3 2011($0.23)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.20)($0.22)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.13)($0.17)ViewN/AView Earnings Details
3/11/2011Q4 2010($0.09)($0.05)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.18)($0.12)ViewN/AView Earnings Details
8/12/2010Q2 2010($0.18)($0.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

CorMedix (NYSEAMERICAN:CRMD) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for CorMedix (NYSEAMERICAN:CRMD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

CorMedix (NYSEAMERICAN CRMD) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for CorMedix (NYSEAMERICAN:CRMD)
Institutional Ownership by Quarter for CorMedix (NYSEAMERICAN:CRMD)

CorMedix (NYSEAMERICAN CRMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017Jr. John L ArmstrongVPBuy20,833$0.48$9,999.8420,833View SEC Filing  
12/12/2017Khoso BaluchCEOBuy104,166$0.48$49,999.68225,373View SEC Filing  
12/12/2017Robert W CookCFOBuy52,083$0.48$24,999.84102,083View SEC Filing  
12/12/2017Steven W LefkowitzDirectorBuy135,416$0.48$64,999.68View SEC Filing  
8/18/2017Khoso BaluchCEOBuy36,207$0.42$15,206.94121,207View SEC Filing  
8/18/2017Mehmood KhanDirectorBuy400,000$0.39$156,000.0050,000View SEC Filing  
8/17/2017Myron KaplanDirectorBuy80,000$0.40$32,000.00180,000View SEC Filing  
8/14/2017Myron KaplanDirectorBuy50,000$0.35$17,500.00100,000View SEC Filing  
5/30/2017Cora M TellezDirectorBuy7,550$0.42$3,171.00182,371View SEC Filing  
5/17/2017Khoso BaluchCEOBuy75,000$0.48$36,000.0085,000View SEC Filing  
5/16/2017Cora M TellezDirectorBuy50,000$0.48$24,000.00174,821View SEC Filing  
5/15/2017Janet DillioneDirectorBuy21,231$0.48$10,190.8839,969View SEC Filing  
5/15/2017Robert W CookCFOBuy50,000$0.50$25,000.0050,000View SEC Filing  
5/1/2017Cora M TellezDirectorBuy4,800$0.66$3,168.00124,821View SEC Filing  
3/30/2017Cora M TellezDirectorBuy1,950$1.66$3,237.00120,021View SEC Filing  
2/28/2017Cora M TellezDirectorBuy1,540$2.10$3,234.00118,071View SEC Filing  
2/7/2017Antony PfaffleInsiderSell10,000$2.00$20,000.0010,000View SEC Filing  
1/30/2017Cora M TellezDirectorBuy1,780$1.79$3,186.20116,531View SEC Filing  
12/30/2016Cora M TellezDirectorBuy1,990$1.58$3,144.20114,751View SEC Filing  
12/9/2016Khoso BaluchCEOBuy10,000$1.77$17,700.0010,000View SEC Filing  
11/30/2016Cora M TellezDirectorBuy1,800$1.80$3,240.00112,761View SEC Filing  
10/31/2016Cora M TellezDirectorBuy1,475$2.15$3,171.25110,961View SEC Filing  
10/21/2016Antony PfaffleInsiderSell20,000$2.23$44,600.0020,000View SEC Filing  
9/22/2016Janet DillioneDirectorBuy15,000$2.66$39,900.0015,000View SEC Filing  
8/25/2016Taunia MarkvickaDirectorBuy18,600$1.65$30,690.0022,600View SEC Filing  
8/19/2016Cora M TellezDirectorBuy12,500$1.73$21,625.00109,486View SEC Filing  
6/21/2016Antony PfaffleInsiderSell29,657$2.14$63,465.9810,000View SEC Filing  
6/20/2016Antony PfaffleInsiderSell10,000$2.16$21,600.0010,000View SEC Filing  
6/15/2016Antony PfaffleInsiderSell4,900$2.21$10,829.004,900View SEC Filing  
6/13/2016Antony PfaffleInsiderSell5,443$2.27$12,355.615,000View SEC Filing  
6/9/2016Antony PfaffleInsiderSell10,000$2.38$23,800.0010,000View SEC Filing  
6/8/2016Janet DillioneDirectorBuy3,738$2.67$9,980.4618,738View SEC Filing  
6/3/2016Matthew DuffyDirectorSell46,106$2.73$125,869.3828,571View SEC Filing  
5/31/2016Steven W LefkowitzDirectorSell50,000$2.88$144,000.00159,599View SEC Filing  
5/25/2016Cora M TellezDirectorBuy8,600$2.90$24,940.0096,986View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.0012,700View SEC Filing  
5/24/2016Antony PfaffleInsiderSell12,700$2.73$34,671.0012,700View SEC Filing  
5/23/2016Antony PfaffleInsiderSell15,000$2.89$43,350.0010,000View SEC Filing  
5/23/2016Steven W LefkowitzDirectorSell30,000$2.93$87,900.00132,525View SEC Filing  
5/19/2016Antony PfaffleInsiderSell12,300$2.82$34,686.0012,300View SEC Filing  
5/16/2016Antony PfaffleInsiderSell60,000$2.68$160,800.0060,000View SEC Filing  
6/30/2015Randy MilbyCEOBuy1,610$3.88$6,246.80View SEC Filing  
6/23/2015Taunia MarkvickaDirectorBuy4,000$4.81$19,240.00View SEC Filing  
6/15/2015Randy MilbyCEOBuy1,245$5.02$6,249.90View SEC Filing  
6/4/2015Matthew DuffyDirectorSell30,000$6.48$194,400.00View SEC Filing  
5/29/2015Randy MilbyCEOBuy1,026$6.09$6,248.34View SEC Filing  
2/27/2015Randy MilbyCEOBuy1,211$5.16$6,248.76View SEC Filing  
2/13/2015Randy MilbyCEOBuy1,911$3.27$6,248.97View SEC Filing  
1/30/2015Randy MilbyCEOBuy2,016$3.10$6,249.60View SEC Filing  
12/15/2014Randy MilbyCEOBuy4,734$1.32$6,248.88View SEC Filing  
11/28/2014Randy MilbyCEOBuy4,464$1.40$6,249.60View SEC Filing  
11/14/2014Cora M TellezDirectorBuy11,086$1.52$16,850.72View SEC Filing  
11/14/2014Randy MilbyCEOBuy4,111$1.52$6,248.72View SEC Filing  
10/31/2014Randy MilbyCEOBuy3,434$1.82$6,249.88View SEC Filing  
9/30/2014Randy MilbyCEOBuy3,324$1.88$6,249.12View SEC Filing  
9/15/2014Randy MilbyCEOBuy3,654$1.71$6,248.34View SEC Filing  
8/29/2014Randy MilbyCEOBuy3,125$2.00$6,250.00View SEC Filing  
8/15/2014Randy MilbyCEOBuy3,140$1.99$6,248.60View SEC Filing  
7/31/2014Randy MilbyCEOBuy6,250$2.00$12,500.00View SEC Filing  
6/30/2014Randy MilbyCEOBuy2,732$1.83$4,999.56View SEC Filing  
12/13/2013Steven W LefkowitzInsiderBuy18,000$0.78$14,040.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CorMedix (NYSEAMERICAN CRMD) News Headlines

Source:
DateHeadline
Why CorMedix Inc. (CRMD) Shares Took a Nosedive TodayWhy CorMedix Inc. (CRMD) Shares Took a Nosedive Today
finance.yahoo.com - February 20 at 5:50 PM
CorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin(R) for Interim Efficacy AnalysisCorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin(R) for Interim Efficacy Analysis
finance.yahoo.com - February 20 at 8:13 AM
CorMedix Inc. (CRMD) Short Interest UpdateCorMedix Inc. (CRMD) Short Interest Update
www.americanbankingnews.com - February 9 at 8:28 PM
Technical Perspectives on Biotech Stocks -- CorMedix, Curis, Cyclacel Pharma, and Cymabay TherapeuticsTechnical Perspectives on Biotech Stocks -- CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics
www.bizjournals.com - February 9 at 9:21 AM
CorMedix Inc. (CRMD) Short Interest Up 8.3% in JanuaryCorMedix Inc. (CRMD) Short Interest Up 8.3% in January
www.americanbankingnews.com - January 24 at 6:10 PM
CorMedix Inc. (CRMD) Short Interest Down 10.2% in DecemberCorMedix Inc. (CRMD) Short Interest Down 10.2% in December
www.americanbankingnews.com - January 11 at 2:36 AM
ETFs with exposure to CorMedix, Inc. : January 1, 2018ETFs with exposure to CorMedix, Inc. : January 1, 2018
finance.yahoo.com - January 1 at 5:12 PM
CorMedix, Inc. :CRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017CorMedix, Inc. :CRMD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 28 at 1:16 PM
Short Interest in CorMedix Inc. (CRMD) Increases By 20.4%Short Interest in CorMedix Inc. (CRMD) Increases By 20.4%
www.americanbankingnews.com - December 27 at 6:38 PM
ETFs with exposure to CorMedix, Inc. : December 19, 2017ETFs with exposure to CorMedix, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 5:16 PM
CorMedix Inc. (CRMD) CFO Robert W. Cook Acquires 52,083 SharesCorMedix Inc. (CRMD) CFO Robert W. Cook Acquires 52,083 Shares
www.americanbankingnews.com - December 14 at 6:50 PM
Khoso Baluch Buys 104,166 Shares of CorMedix Inc. (CRMD) StockKhoso Baluch Buys 104,166 Shares of CorMedix Inc. (CRMD) Stock
www.americanbankingnews.com - December 14 at 6:28 PM
CorMedix Inc. (CRMD) Director Steven W. Lefkowitz Acquires 135,416 SharesCorMedix Inc. (CRMD) Director Steven W. Lefkowitz Acquires 135,416 Shares
www.americanbankingnews.com - December 14 at 6:26 PM
ETFs with exposure to CorMedix, Inc. : December 7, 2017ETFs with exposure to CorMedix, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:43 PM
CorMedix Inc. Announces Acceptance of Final Post-Marketing Study Data to be Published in the European Journal of Clinical Microbiology and Infectious DiseasesCorMedix Inc. Announces Acceptance of Final Post-Marketing Study Data to be Published in the European Journal of Clinical Microbiology and Infectious Diseases
finance.yahoo.com - December 5 at 10:14 AM
CorMedix Inc (CRMD): Should The Recent EPS Drop Worry You?CorMedix Inc (CRMD): Should The Recent EPS Drop Worry You?
finance.yahoo.com - December 4 at 5:16 PM
CorMedix Inc. to Host Seminar on Hemodialysis Catheter Complications at 17th Annual Conference on NephrologyCorMedix Inc. to Host Seminar on Hemodialysis Catheter Complications at 17th Annual Conference on Nephrology
finance.yahoo.com - November 29 at 9:37 AM
Short Interest in CorMedix Inc. (CRMD) Grows By 21.6%Short Interest in CorMedix Inc. (CRMD) Grows By 21.6%
www.americanbankingnews.com - November 27 at 7:48 PM
CorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management TeamCorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management Team
finance.yahoo.com - November 20 at 6:34 PM

SEC Filings

CorMedix (NYSEAMERICAN:CRMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CorMedix (NYSEAMERICAN:CRMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CorMedix (NYSEAMERICAN CRMD) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.